Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
复制标题
三重阴性乳腺癌中肿瘤浸润的淋巴细胞：免疫靶向的未来。
DOI：
10.4137/cmo.s34540
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Pérez YF
中科院分区：
文献类型：
--
作者：
García-Teijido P;Cabal ML;Fernández IP;Pérez YF
三阴性乳腺癌（TNBC）是一种高度异质性的肿瘤。有越来越多的证据表明，肿瘤淋巴细胞免疫浸润在这种亚型的乳腺癌中的作用。稳健水平的肿瘤浸润淋巴细胞（TIL）与有和无任何治疗的TNBC患者中改善的无病存活率和总存活率相关。最近已作出努力，制定一个标准化的方法来评价TILs。乳腺肿瘤微环境中TIL的存在不仅可以预测对新辅助化疗的反应，还可以预测对辅助化疗的反应。高数量的TIL与TNBC中增加的病理完全应答（pCR）相关。TIL是预后和预测对标准疗法的反应;因此，免疫系统似乎在乳腺癌亚组中发挥积极作用。人们越来越关注直接靶向免疫系统作为乳腺癌治疗的一部分，主要是在TNBC患者中。新的免疫调节剂，包括免疫检查点抑制剂，已经在转移性TNBC亚组中显示出有希望的活性。TNBC表面上程序性细胞死亡蛋白1配体（PD-L1）表达的增加为在TNBC中实施靶向PD-1/PD-L1轴的治疗策略提供了理论基础。程序性细胞死亡蛋白1（PD-1）抑制剂pembrolizumab和PD-L1抑制剂atezolizumab在临床试验中显示出有希望的结果。
Triple negative breast cancer (TNBC) is a highly heterogeneous tumor. There is increasing evidence of the role of tumor lymphocytic immune infiltrates in this subtype of breast cancer. Robust levels of tumor infiltrating lymphocytes (TILs) have been associated with improved disease-free and overall survival rates in TNBC patients with and without any treatment. Recent efforts have been made to develop a standardized methodology for evaluating TILs. The presence of TILs in the breast tumor microenvironment can also predict responses not only to neoadjuvant but also to adjuvant chemotherapy treatments. High numbers of TILs correlate with increased pathological complete responses (pCR) in TNBC. TILs are prognostic and predictive of response to standard therapies; thus, the immune system appears to play an active role in a subgroup of breast cancer. There is an increasing interest in directly targeting the immune system as part of breast cancer therapy, mainly in patients with TNBC. New immune modulatory agents, including immune checkpoints inhibitors, have shown promising activity in a subgroup of metastatic TNBC. Increased programmed cell death protein 1 ligand (PD-L1) expression on the surface of TNBC provides the rationale for implementing therapeutic strategies targeting the PD-1/PD-L1 axis in TNBC. The programmed cell death protein 1 (PD-1) inhibitor pembrolizumab, and the PD-L1 inhibitor atezolizumab have shown promising results in clinical trials.